Please assess the completion status of the following clinical trial:

Trial Title: DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who are competent to provide written consent~* Aged 35 to 80 years~* Subjects with diabetes and/or chronic kidney disease must have a mean systolic blood pressure ≥130 mmHg~* All other subjects must have a mean systolic blood pressure ≥140 mmHg~* Receiving and adhering to full doses of appropriate guideline-recommended antihypertensive drugs from three different classes of antihypertensive agents, including a diuretic~* Female subjects of non-childbearing potential (i.e., post-menopausal for at lest 2 years; surgically sterile)~Exclusion Criteria:~* Average sitting systolic blood pressure ≥180 mmHg or diastolic blood pressure ≥110 mmHg~* Serum ALT or AST \>2 x the upper limit of the normal range (ULN)~* Subjects who have experienced myocardial infarction, unstable angina pectoris, or a cerebrovascular accident (CVA) within 6 month; or sick sinus syndrome or second or third degree atrioventricular block, atrial fibrillation or recurrent atrial tachyarrhythmia, recurrent ventricular tachycardia, or symptomatic bradycardia~* Implanted pacemakers or implanted cardioverter defibrillator (ICD)~* Symptomatic congestive heart failure requiring treatment~* Hemodynamically significant valvular heart disease~* Type I diabetes mellitus~* Hemodialysis or peritoneal dialysis; or history of renal transplant~* Diagnosis or recurrence of malignancy within the past 3 years~* Sleep apnea, unless a recent sleep study demonstrates arterial oxygen saturation greater than or equal to 90%~* Subjects who perform alternating shift or night work~* Subjects who have participated in a clinical study involving another investigational drug or device within 4 weeks prior to Screening

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Darusentan Placebo (Type: PLACEBO_COMPARATOR): Placebo to match darusentan for 2-week placebo run-in period, followed by placebo to match darusentan administered orally once daily for 14 weeks
- Darusentan 50 mg (Type: EXPERIMENTAL): Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan 50 mg administered orally once daily for 14 weeks
- Darusentan 100 mg (Type: EXPERIMENTAL): Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan 100 mg administered orally once daily for 14 weeks
- Darusentan 300 mg (Type: EXPERIMENTAL): Placebo to match darusentan for 2-week placebo run-in period, followed by darusentan 300 mg administered orally once daily for 14 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).